Kinase Inhibitor
Everolimus + Sorafenib for Thyroid Cancer
Recruiting1 awardPhase 2
Basking Ridge, New Jersey
This trial is testing a combination of two pills, sorafenib and everolimus, to treat thyroid cancer. Sorafenib cuts off the tumor's blood supply, while everolimus blocks a protein that helps cancer cells grow. Everolimus is approved for various cancers, including breast cancer, and has shown promise in combination therapies. The study aims to see if this combination works better than current treatments.
Alkylating Agent
Sorafenib + Chemotherapy for Acute Myeloid Leukemia
Recruiting1 awardPhase 1 & 2
Houston, Texas
This trial tests the best dose of sorafenib combined with busulfan and fludarabine for patients with hard-to-treat acute myeloid leukemia. Sorafenib blocks enzymes needed for cancer growth, while busulfan and fludarabine kill or stop the spread of cancer cells. Sorafenib has shown potential in early studies for treating acute myeloid leukemia.
Popular Filters
Phase 3 Trials
Checkpoint Inhibitor
Immunotherapy for Liver Cancer
Recruiting2 awardsPhase 3
Los Angeles, California
This trial is testing whether two immunotherapy drugs or one immunotherapy drug is better than the standard-of-care drug for people with liver cancer that can't be removed by surgery and who haven't gotten any other systemic therapy.
Checkpoint Inhibitor
Nivolumab + Ipilimumab for Liver Cancer
Recruiting2 awardsPhase 3
Tucson, Arizona
This trial is testing a combination of two drugs, nivolumab and ipilimumab, which help the immune system fight cancer. It targets patients with advanced liver cancer who haven't received any previous whole-body treatments. The goal is to see if these drugs can help patients live longer compared to standard treatments. Nivolumab and ipilimumab have been used in combination to treat various advanced cancers, showing promising results but with higher side effects compared to using a single drug.
Trials With No Placebo
Proton Beam Therapy
Multimodal Therapy for Rhabdomyosarcoma
Recruiting1 awardPhase 2
Jacksonville, Florida
This trial will treat people with newly diagnosed rhabdomyosarcoma with different intensities of chemotherapy, radiation and surgery based on how high-risk the cancer is. For the intermediate and high risk patients, they will receive an additional 12 weeks of maintenance therapy with anti-angiogenic chemotherapy.
Proteasome Inhibitor
Bortezomib + Sorafenib + Decitabine for Acute Myeloid Leukemia
Recruiting1 awardPhase 1
Columbus, Ohio
This trial is testing bortezomib and sorafenib tosylate given with decitabine to see what effects (good and bad) it has on patients with acute myeloid leukemia, and to find the best dose of the drugs to use.
Chemotherapy
Riluzole + Sorafenib for Melanoma
Recruiting1 awardPhase 1
New Brunswick, New Jersey
This trial tests the safety and best dose of combining riluzole and sorafenib tosylate for patients with advanced solid tumors or melanoma that don't respond to standard treatments. Riluzole may slow tumor growth, and sorafenib tosylate blocks processes needed for tumor growth. The combination aims to kill more tumor cells.
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.